BFS
ATRA icon

Bradley Foster & Sargent’s Atara Biotherapeutics ATRA Stock Holding History

Bradley Foster & Sargent’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-663
Closed -$261K – 470
2021
Q4 		$261K Buy
+663
New +$279K 0.01% 406

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bradley Foster & Sargent's ATRA Position: Q1 2022 in Review

Bradley Foster & Sargent sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 663 shares — an estimated $261K sold.

Bradley Foster & Sargent first reported a position in ATRA in Q4 2021 and held it in 1 quarter. The position peaked at $261K in Q4 2021. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Bradley Foster & Sargent reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Bradley Foster & Sargent sold 663 Atara Biotherapeutics shares in Q1 2022, an estimated $261K.
  • Bradley Foster & Sargent first reported a position in Atara Biotherapeutics in Q4 2021 and held it in 1 quarter.
  • Bradley Foster & Sargent's Atara Biotherapeutics position peaked at $261K in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Bradley Foster & Sargent's 13F filing for Q1 2022, filed 16 May 2022.